Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
